The Use of First Line Highly Active Anti-Retroviral Therapy (HAART) is Not Associated with Qtc Prolongation in HIV Patients.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read Online Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Research and Publications Office of Jimma University Country of Publication: Ethiopia NLM ID: 101224773 Publication Model: Print Cited Medium: Internet ISSN: 2413-7170 (Electronic) Linking ISSN: 10291857 NLM ISO Abbreviation: Ethiop J Health Sci Subsets: MEDLINE
    • Publication Information:
      Original Publication: Jimma, Ethiopia : Research and Publications Office of Jimma University
    • Subject Terms:
      Anti-HIV Agents*/adverse effects ; Antiretroviral Therapy, Highly Active*/adverse effects ; CD4 Lymphocyte Count* ; Cardiac Conduction System Disease*/etiology; HIV Infections/*drug therapy; Adult ; Cross-Sectional Studies ; Electrocardiography ; Female ; HIV Infections/virology ; Humans ; Logistic Models ; Male ; Middle Aged ; Risk Factors
    • Abstract:
      Background: HAART has improved survival of HIV patients. Its contribution to the development of new cardiovascular abnormalities has generated much interest. This study aimed at determining the prevalence of QTc prolongation among HIV patients and determining the influence if any of the use of HAART on the QTc and on the risk of having QTc prolongation.
      Materials and Methods: One hundred and fifty HIV positive subjects comprising 76 HIV positive subjects on HAART (Group A), 74 who were HAART- naïve (Group B), and 150 age and sex-matched healthy controls (Group C) were studied. All subjects had electrocardiography, and QTc duration was calculated.
      Results: Mean QTc was significantly different among the three groups (P <0.001), highest in Group B > Group A > Group C. Frequency of QTc prolongation was highest in Group B (32%)>, Group A (17.3%)> Group C (4.7%) (P<0.001). Mean QTc was significantly longer among patients with CD4 count <200 cells/mm 3 than among those with >200 cells/mm 3 0.445 ± 0.03secs vs 0.421 ± 0.03secs (P<0.001). QTc prolongation was commoner among individuals with CD4 count <200 cells/mm 3 50% vs 20.5% (P<0.001). On binary logistic regression, none of the HAART medications used by our patients was predictive of the occurrence of QTc prolongation.
      Conclusion: The QTc is longer, and QTc prolongation occurs more frequently in HAART-naïve HIV patients than patients on HAART and healthy controls. None of the HAART medications used by our patients was predictive of the development of QTc prolongation.
    • References:
      Cardiovasc J Afr. 2016 Jul/Aug;27(4):252-257. (PMID: 27841913)
      Niger J Med. 2005 Jul-Sep;14(3):255-60. (PMID: 16350692)
      J Electrocardiol. 2006 Apr;39(2):199-205. (PMID: 16580420)
      Am J Cardiol. 1991 Jan 1;67(1):55-8. (PMID: 1986505)
      J Cardiovasc Med (Hagerstown). 2017 Jul;18(7):539-544. (PMID: 27635938)
      J Am Coll Cardiol. 2017 Jan 3;69(1):83-91. (PMID: 28057254)
      Clin Infect Dis. 2007 May 15;44(10):1388-9; author reply 1389-91. (PMID: 17443482)
      Int J Cardiol. 1993 Oct 1;41(3):225-32. (PMID: 8288412)
      J Acquir Immune Defic Syndr. 2015 Feb 1;68(2):209-16. (PMID: 25588033)
      Postgrad Med J. 2002 Nov;78(925):678-81. (PMID: 12496326)
      Br J Clin Pharmacol. 2010 Jul;70(1):16-23. (PMID: 20642543)
      J Natl Med Assoc. 2005 Dec;97(12):1657-61. (PMID: 16396057)
      Ann Afr Med. 2015 Oct-Dec;14(4):169-76. (PMID: 26470741)
      J Am Coll Cardiol. 2012 May 22;59(21):1891-6. (PMID: 22595409)
      Prog Cardiovasc Dis. 2001 Mar-Apr;43(5 Suppl 1):1-45. (PMID: 11269621)
      Pacing Clin Electrophysiol. 1997 Nov;20(11):2810-6. (PMID: 9392812)
      J Mol Cell Cardiol. 2007 Dec;43(6):710-6. (PMID: 17961593)
      Am J Pathol. 1983 Sep;112(3):357-82. (PMID: 6311021)
      Am Heart J. 2002 Oct;144(4):642-8. (PMID: 12360160)
      J Biol Chem. 2004 Apr 2;279(14):13289-92. (PMID: 14973143)
      Front Cardiovasc Med. 2015 May 27;2:26. (PMID: 26798623)
      J HIV Ther. 2009 Nov;14(3):52-6. (PMID: 20218239)
      Cardiovasc J Afr. 2012 Sep;23(8):e1-6. (PMID: 22907266)
      J Electrocardiol. 2011 Nov-Dec;44(6):779-85. (PMID: 21145066)
      HIV Clin Trials. 2009 Jul-Aug;10(4):261-8. (PMID: 19723613)
      Immunol Rev. 2013 Jul;254(1):78-101. (PMID: 23772616)
      Cardiovasc Res. 1993 Mar;27(3):525-30. (PMID: 8490954)
      Lancet. 2005 Feb 19-25;365(9460):682-6. (PMID: 15721475)
      J Infect. 2007 Jun;54(6):597-602. (PMID: 17174400)
      Clin Auton Res. 1995 Feb;5(1):48-52. (PMID: 7780290)
    • Contributed Indexing:
      Keywords: HIV/AIDS; Highly Active Anti-Retroviral Therapy (HAART); QTc prolongation
    • Accession Number:
      0 (Anti-HIV Agents)
    • Publication Date:
      Date Created: 20180301 Date Completed: 20180830 Latest Revision: 20231112
    • Publication Date:
      20231112
    • Accession Number:
      PMC5811940
    • Accession Number:
      10.4314/ejhs.v27i6.6
    • Accession Number:
      29487470